Amineptine
Amineptine, formerly sold under the brand name Survector among others, is an atypical antidepressant of the tricyclic antidepressant (TCA) family. It acts as a selective and mixed dopamine reuptake inhibitor and releasing agent, and to a lesser extent as a norepinephrine reuptake inhibitor.

Amineptine was developed by the French Society of Medical research in the 1960s. Introduced in France in 1978 by the pharmaceutical company Servier, amineptine soon gained a reputation for abuse due to its short-lived, but pleasant, stimulant effect experienced by some patients.

After its release into the European market, cases of hepatotoxicity emerged, some serious. This, along with the potential for abuse, led to the suspension of the French marketing authorization for Survector in 1999.

Amineptine was never approved by the U.S. Food and Drug Administration (FDA) for marketing in the United States, meaning that it is not legal to market or sell amineptine for any medical uses in the U.S.
Q39045298
atypical antidepressant
Concept
Q908843
tricyclic antidepressant
Concept
Q4914025
selective
Concept
Q899647
dopamine reuptake inhibitor
Concept
Q18352328
releasing agent
Concept
Q899668
norepinephrine reuptake inhibitor
Concept
Q12140
pharmaceutical
Concept
Q907487
Servier
ORG
Q211036
stimulant
Concept
Q46
Europe
LOC
Q1349821
hepatotoxicity
Concept
Q204711
Food and Drug Administration
Concept
Q44822059
Amineptine
Concept
Q44822059
Amineptine
Concept
Q44822059
Amineptine
Concept
1960-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1960
DATE
1978-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1978
DATE
1999-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1999
DATE
subject has role
instance of
manufacturer